Navigation Links
Navitas Names Dr. Dean Gesme as Medical Director
Date:10/17/2007

DENVER, Oct. 17 /PRNewswire/ -- Navitas Cancer Rehabilitation Centers of America, Inc. (Navitas), the market leader in providing integrated and comprehensive cancer rehabilitation services, is pleased to announce the appointment of Dean H. Gesme, Jr., M.D. as Corporate Medical Director.

In addition to currently providing care as a medical oncologist in the Minneapolis/St. Paul area, Dr. Gesme has served as the Past-Chair of the National Coalition for Cancer Survivorship and is Past-Chair of the Clinical Practice Committee of the American Society of Clinical Oncology. He has been the Oncology Representative on the AMA CPT Advisory Panel dealing with physician coding, and payment issues. Dr. Gesme is board certified in Internal Medicine, Medical Oncology, and Medical Management. Dr. Gesme attended medical school at the University of Iowa and completed his residency training in Internal Medicine in San Francisco and his fellowship in Medical Oncology at the University of Minnesota.

"Navitas has a tremendous opportunity to serve cancer survivors and Dr. Gesme is perfectly suited to provide medical leadership to this vision," shared Paul Barnes, Ph.D., President and CEO for Navitas. "Dean has devoted his career to the patient advocacy community as well to the treatment of cancer patients. We are fortunate to have him join our management team at Navitas.

"I have been impressed by the clinical basis of the cancer rehabilitation program at Navitas," Dr. Gesme stated. "I look forward to the day where rehabilitation services for cancer patients are as much the standard of care as is true for cardiac and other areas of medicine. Cancer patients deserve no less. I look forward to contributing to the clinical research efforts at Navitas to make that happen."

About Navitas Cancer Rehabilitation Centers of America

Founded in 2003, Navitas Cancer Rehabilitation Centers of America (http://www.navitasinc.com) developed an evidence-based approach to providing rehabilitation and supportive therapies to people with cancer. Navitas provides these services on a free-standing basis as well as through community-based and hospital-based oncology centers and practices. The Navitas vision is to make supportive and rehabilitation services a standard component of the cancer treatment plan through the development of a robust, multi-disciplinary clinical program and demonstrated outcomes for patients and physicians. Navitas is headquartered in Denver, Colorado.

http://www.navitasinc.com

Media Contact:

Shaun Burns

303-865-7840

sburns@navitasinc.com


'/>"/>
SOURCE Navitas Cancer Rehabilitation Centers of America
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Wisconsin IT association names Gee president, CEO
2. Quintessence Biosciences names new president
3. CDW names VP to handle Berbee merger
4. NimbleGen names CFO with capital-raising past
5. Cisco names Berbee a top partner of 2005
6. Cisco names Inacom most innovative partner
7. UW-Madison medical school names new dean
8. GE Healthcare names new CEO
9. Bruker AXS names new leadership
10. Sonic Foundry names new senior vice president
11. MyWeather names new president, marketing officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 05, 2016 , ... CereScan, the nation’s ... Stroke Association during National Stroke Awareness Month in May. An infographic created ... the month. CereScan will donate $1 up to a maximum of $3,000 ...
(Date:5/4/2016)... Diego, CA (PRWEB) , ... May 04, 2016 ... ... Day? Well, look no further than LaJollaCooks4u, San Diego’s premiere hands-on cooking experience. ... you need to give mom an experience she won’t forget. , Guests that ...
(Date:5/4/2016)... ... , ... Proove Biosciences, Inc. , the commercial and research leader in ... . The partnership is designed to advance research in pain genetics in an effort ... With the new agreement, researchers at Proove Biosciences are able to collaborate with Luda ...
(Date:5/4/2016)...  Bayer today announced that a Phase III ... (regorafenib) tablets for the treatment of patients with ... endpoint of a statistically significant improvement in overall ... and safety of regorafenib in patients with HCC ... The safety and tolerability were generally consistent with ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
Breaking Biology News(10 mins):